Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...
Discover the molecular mechanisms behind severe blood clots linked to specific COVID-19 vaccines, revealing crucial insights for future vaccine safety.
Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Neumega Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...
Patients with lupus nephritis complicated by thrombotic microangiopathy tend to have high death risk and poor renal outcomes. They need vital and effective therapies.
An urgent call is going out for blood donors as Hoxworth Blood Centers says supplies are running low, especially for Type O ...
Leerink Global Healthcare Conference 2026 March 10, 2026 9:20 AM EDTCompany ParticipantsPablo Cagnoni - President and Head ...
Good afternoon, and welcome to the Galectin Therapeutics Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Galectin ...
Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...
When 28-year-old mother Rachita Ramesh felt constant fatigue after childbirth, she blamed postpartum exhaustion, until unusual bleeding revealed Acute Lymphoblastic Leukaemia, leading to chemotherapy ...
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 ...
During a live event, Joshua Richter, MD, explored proactive adverse event management when using selinexor in multiple myeloma. At a live Case-Based Roundtable event during the 2025 American Society of ...
5d
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results